By Juliette Fairley
Consumers who struggle with frequent toothaches now have a cannabis alternative to treat inflammation. AXIM Biotech (OTCQB: AXIM) has introduced Oraximax, the first ever Cannabigerol-based product line, which consists of toothpaste, dentifrice and mouthwash.
“There are 320 toothpastes on the market, which are all very similar,” said Dr. George Anastassov, a dentist and CEO with AXIM Biotech, a biotechnology company based in the United States. “They prevent cavities and promote fresh breath but AXIM’s CBG derived oral care products eliminate the multiple bacteria that accummulates in the mouth from the repeated trauma of eating, talking and tooth brushing.”
CBG oral care products are expected to be available online and in stores in the U.S. by third quarter 2015.
“We work with a strain of industrial hemp that has high levels of CBGs and no THC, which we purchase from a producer in Italy,” said Dr. Philip Van Damme, a doctor and chief medical officer with AXIM Biotech. According to Van Damme, “The compound also kills tumors and reduces eye pressure in glaucoma patients.”
CBG is among 85 cannabinoid compounds found in the marijuana plant, which reportedly have anti-inflammatory as well as anti-bacterial properties.
“It can help with gingivitis and bleeding gums,” Anastassov said.
The company is also testing CBD and THC as an analgesic for relief of muscle spasms and cramps in clinical trials at the Free University of Amsterdam in the Netherlands, the University of Plymouth in Great Britain as well as Boston University.
“The world population is aging with an active lifestyle, which can cause pain so there’s a need for new pain treatments without side effects,” Van Damme said. “There are no new classes of analgesics on the market, only NSAIDs and opioids and the combinations of these.”
The most well known among CBDs is tetrahydrocannabinol (THC), which is what creates the psychoactive impact of ingesting marijuana.
Although AXIM Biotech uses a proprietary strain called Asso, the company’s research and development team is stopping short of launching CBG-based edibles. “Chewing gum or tinctures absorbed under the tongue is a better delivery method,” Anastassov said.
“Our FDA approval is in process and we have patents in 125 countries with nine pending in the U.S,” Anastassov added.
The firm is also developing an anti-aging skin care line called RENECANN that will be sold over the counter. “It eliminates redness, hydrates and rejuvenates the skin as well as increases the level of elastin and quality of collagen in the skin,” said Lekhram Changoer, chief technology officer with AXIM Biotech.